September 18, 2024 – The number of lives lost around the world due to infections that are resistant to the medications intended to treat them could increase nearly 70% by 2050, a new study just published in the journal The Lancet estimates.

Cumulatively, from 2025 to 2050, the world could see more than 39 million deaths that are directly attributable to antimicrobial resistance or AMR. It is important that interventions combine infection prevention, vaccination, minimisation of inappropriate antibiotic use in farming and humans, and research into new antibiotics to mitigate the number of AMR deaths that are forecasted for 2050.

TenNor is developing multiple new antimicrobial drugs with a novel mechanism of action to address the AMR challenges.

TNP-2198 is a synergistic multitargeting drug candidate currently under phase 3 clinical development for the treatment of Helicobacter pylori infections. TNP-2198 is the first new drug in 30 years specifically developed for H. pylori. TNP-2198 can overcome multidrug resistance to antibiotics currently used for the treatment of H. pylori infections.

TNP-2092 is a novel triple acting antibacterial agent with an excellent activity against multidrug resistant Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and quinolone-resistant S. aureus (QRSA). TNP-2092 possesses an extremely low frequency for the development of resistance. TNP-2092 is currently under phase 3 clinical development for the treatment of prosthetic joint infections.

Link to Lancet article:

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01076-6/fulltext

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01867-1/fulltext

About TenNor Therapeutics

TenNor Therapeutics is a clinical-stage company specialized in the discovery and development of differentiated new drug products in diseases associated with bacterial infection and metabolism. TenNor possesses a unique multi-targeting drug conjugate technology platform and a strong new drug development pipeline with global IP protection. Several products are currently in late-stage of clinical development targeting H. pylori infection, implanted medical device infections, hepatic encephalopathy and irritable bowel syndrome with diarrhea. The company is committed to address the unmet needs in the disease area and provide safe and effective therapies for patients in China and around the world.

For more information, please visit: www.tennorx.com